Clinical Trial Update: Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors [Phase 1]

View source ↗

Summary

This Phase I trial evaluated oral metronomic topotecan in combination with pazopanib for recurrent/persistent gynecologic tumors; the study has completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Tumors

Drugs mentioned

• Pazopanib (Pazopanib)
• Topotecan (topotecan)

Snippet

Sponsor: Vector Oncology | Conditions: Gynecologic Tumors | Phase 1 | Status: COMPLETED | Results posted: 2017-02-23